30 closest matches · ranked by relevance
Improve Endothelial Function and Decrease Vascular Stenosis
Primary: Change in Baseline and 2 Week FMD/VP Measurements Between Sildenafil Group and Placebo Group — 10.8; 8.6 Change in FMD%
Chronic Kidney Disease
Primary: Maximal Oxygen Uptake — 14.5; 15.1 ml/kg/min
Chronic Kidney Disease · Secondary Hyperparathyroidism
Primary: Achievement of a ≥ 30% Reduction in Mean PTH From Baseline to During the Efficacy Assessment Phase at Month 6 (Weeks 22 to 26) — 96; 58; 57; 93 participants — p=<0.0001
ESRD
Primary: Change in Leucine Disposal Rate (LDR) — -0.011; 0.005; 0.001 mg/kg/min — p=0.37
Anemia · End Stage Renal Disease (ESRD)
Primary: Change From Baseline (BL) to the Average Hemoglobin (Hb) in Weeks 28-36 Without Rescue Therapy [EU (EMA)] — 0.428; 0.193 g/dL — p=<0.001
Hypertension · End Stage Renal Disease
Primary: Change in Mean Interdialytic 44-hour Ambulatory Systolic Blood Pressure Over a 2 Week Follow-up Period — -1.5; -3.7; -0.4 mm Hg
End-Stage Renal Disease (ESRD)
Primary: Number of Participants With Adverse Events (AEs) — 8 participants
Chronic Renal Anemia
Primary: Time to Composite of All-Cause Mortality and Non-Fatal Cardiovascular Events (Myocardial Infarction, Stroke) Defined as Time Between First Dose of Study Medication and…
End Stage Renal Disease
Primary: Reduction Ratio of Lambda Immunoglobulin FLC at Week 24 — 32.156; 17.514 percentage ratio
End Stage Renal Disease on Hemodialysis (Diagnosis)
Primary: Percentage of Subjects Reporting Clinically Significant Adverse Events - Medically-attended Adverse Events, Serious Adverse Events, and Immune-mediated Adverse Events of…
End Stage Renal Disease
Primary: Dyad Congruence on Goals-of-Care Tool — 98; 76; 133; 119 dyads
End Stage Renal Disease · Anemia
Primary: Number of Participants With Week 7 Hb ≥ Baseline Hb - 0.5 g/dL, Among Normoresponder Participants Treated for 6 Weeks Only — 4; 8; 7; 4 Participants — p=1.0000
Hemodialysis · Kidney Failure, Chronic
Primary: QOL: Kidney Disease Quality of Life (KDQOL36) — 74; 72 score on a scale
End Stage Renal Disease · Chronic Kidney Diseases
Primary: Mean Feasibility of Intervention Measure — 16.4; 16.1; 19.0 score on a scale
Chronic Kidney Disease
Primary: Mortality — 0; 0 percentage of mortality
End-stage Renal Disease (ESRD)
Primary: Number of Participants With Major Bleeding (MB) and Clinically Relevant Non-Major Bleeding (CRNMB) — 3; 2; 3; 3 Participants
End Stage Renal Disease · Thrombosis
Primary: The Number of Subjects With Treatment-related Adverse Events (TEAEs) and the Number of TEAEs Will be Summarized Using Frequency Counts (Safety and Tolerability) — 0; 0…
Renal Insufficiency, Chronic
Primary: Number of Participants With Sufficient Patency for Clinical Access — 20 Participants
End-Stage Renal Disease (ESRD)
Primary: Percent of Subjects Whose Hemoglobin (Hgb) Decreases by a Total of 1.0 Grams/ Deciliter (g/dL) (or More) From Baseline on Each of Two Successive Measurements. — 5; 6; 5…
Chronic Kidney Disease · End Stage Renal Disease
Primary: Change in IGF-1 After 30 Days of Intervention Compared to Baseline Level. — 92.7; 6.7 ng/ml — p=<0.001
Chronic Kidney Diseases · Patient Requiring Heparin Free Dialysis Treatments
Primary: The Primary Endpoint is the Number and Percent (%) of Successful Heparin-free HD Sessions for Each Subject in Each Circuit. — 2.4; 2.9 number of successful HD sessions
Hyperkalemia
Primary: Incidence of Pre-dialysis HK After the LIDP in <3K Dialysate Patients — 50; 37 Percent of participants
End Stage Renal Disease
Primary: Number of Participants With Mean PTH ≤ 300 pg/mL — 262; 41 Participants — p=<0.001
End-Stage Renal Disease
Primary: Change in Monocyte VDR Expression With Vitamin D Therapy — 1899 units on a scale
Anemia, Iron Deficiency · Hyperphosphatemia · Renal Insufficiency, Chronic
Primary: Number of Participants Achieving a Composite Endpoint of Initiation of Maintenance Dialysis or All-cause Mortality — 35; 46 Participants — p=.1602
Chronic Kidney Disease
Primary: Patient Activation Measure (PAM) -13 Item Questionnaire — 9.1; -1.4 points — p=0.01
Anaemia · Haemodialysis
Primary: Haemoglobin Increase of Greater or Equal to 5g/l Following Receipt of Treatment — 53; 61 Participants
End Stage Renal Disease · Chronic Kidney Disease Stage 5 · ESRD
Primary: Change in Mean Weekly Interdialytic Weight Gain (IDWG) — -0.26; -0.23 kilograms — p=0.46
End-stage Renal Disease (ESRD)
Primary: Peak Oxygen Consumption — 3.07 ml/min/kg
Chronic Kidney Disease
Primary: Preference for Shared Decision Making — 22; 19; 35; 44 participants